Growing at an annualized rate of over 16.5%, the cell therapy manufacturing market is estimated to reach close to USD 11 Billion by 2030, claims Roots Analysis

The approval of KYMIRAH®, YESCARTA®, Alofisel® and Zyntelgo® has increased the interest of pharma stakeholders in cell therapies; further, owing to the technical challenges in this field, outsourcing manufacturing operations has become a necessity

For additional details, please visit
https://www.rootsanalysis.com/reports/view_document/cell-therapy-manufacturing/285.html
 

comments (0)

47 more from jameshebrew